✦ LIBER ✦

High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia

✍ Scribed by Hon Y. Chan; Frederick J. Meyers; Jerry P. Lewis

Publisher: Springer
Year: 1987
Tongue: English
Weight: 147 KB
Volume: 20
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00570500

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of acute nonlymphocytic leukem

Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside

✍ Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 1 views

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours

Treatment of “poor risk” acute nonlympho

Treatment of “poor risk” acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside

✍ Dr. Edward P. Balaban; John V. Cox; Nancy R. Schneider; Cheryl A. Harth; Barbara 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

Treatment of childhood acute lymphoblast

Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin

✍ Ishii, Eiichi ;Hara, Toshiro ;Ohkubo, Kenshi ;Matsuzaki, Akinobu ;Takeuchi, Taka 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB

Intermediate-dose cytosine arabinoside a

Intermediate-dose cytosine arabinoside and amsacrine an effective regimen with low toxicity in refractory acute nonlymphocytic leukemia

✍ Adriaan W. Dekker; H. Karel NieuwenhuisKarel; Leo F. Verdonck 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 410 KB 👁 2 views

Treatment of relapsed and refractory acu

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

✍ Martin Gore; Ray Powles; Anil Lakhani; Sarah Milan; Jennifer Maitland; Glen Goss 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 425 KB

A total of 65 patients under the age of 55 with acute leukaemia received high-dose cytosine arabinoside (Ara-C) in combination with high-dose etoposide without an anthracycline. Complete remission rates for patients with relapsed or refractory acute myelogenous leukaemia (AML) were 15/25 (60%) and 1

High-dose cytosine arabinoside intensifi

High-dose cytosine arabinoside intensification for acute nonlymphocytic leukemia in patients over 56 years of age

✍ A. Ferrant; C. Doyen; A. Delannoy; L. Van den Bossche; P. Martiat; V. Deneys; M. 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 526 KB